Monopar Breathes New Life Into AstraZeneca’s Wilson Disease Drug

Despite a successful Phase III study of ALXN-1840 for the inherited disorder that prevents the liver from filtering copper out of the body, the UK major's rare disease division Alexion pulled the plug on the program last summer. However, Illinois-based biotech Monopar is confident in its potential.